Assessment of myocardial extracellular volume on body computed tomography in breast cancer patients treated with anthracyclines by C.B. Monti et al.
© Quantitative Imaging in Medicine and Surgery. All rights reserved.   Quant Imaging Med Surg 2020;10(5):934-944 | http://dx.doi.org/10.21037/qims.2020.04.05
Original Article
Assessment of myocardial extracellular volume on body computed 
tomography in breast cancer patients treated with anthracyclines
Caterina Beatrice Monti1, Moreno Zanardo1, Tommaso Bosetti2, Marco Alì3,4, Elena De Benedictis5, 
Alberto Luporini6, Francesco Secchi1,4, Francesco Sardanelli1,4
1Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy; 2Medicine and Surgery 
School, Università degli Studi di Milano, Via Festa del Perdono 7, 20122 Milan, Italy; 3Unit of Diagnostic Imaging and Stereotactic Radiosurgery, 
CDI Centro Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147 Milan, Italy; 4Unit of Radiology, 5Unit of Oncology I, 6Unit of Oncology II, 
IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Italy
Correspondence to: Dr. Moreno Zanardo. Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Mangiagalli 31, 20133 
Milan, Italy. Email: moreno.zanardo@unimi.it.
Background: Cancer treatment with anthracyclines may lead to an increased incidence of cardiac disease 
due to cardiotoxicity, as they may cause irreversible myocardial fibrosis. So far, the proposed methods 
for screening patients for cardiotoxicity have led to only limited success, while the analysis of myocardial 
extracellular volume (mECV) at cardiac magnetic resonance (CMR) has shown promising results, albeit 
requiring a dedicated exam. Recent studies have found strong correlations between mECV values obtained 
through computed tomography (CT), and those derived from CMR. Thus, our purpose was to evaluate the 
feasibility of estimating mECV on thoracic contrast-enhanced CT performed for staging or follow-up in 
breast cancer patients treated with anthracyclines, and, if feasible, to assess if a rise in mECV is associated 
with chemotherapy, and persistent over time.
Methods: After ethics committee approval, female patients with breast cancer who had undergone at 
least 2 staging or follow-up CT examinations at our institution, one before and one shortly after the 
end of chemotherapy including anthracyclines were retrospectively evaluated. Patients without available 
haematocrit, with artefacts in CT images, or who had undergone radiation therapy of the left breast were 
excluded. Follow-up CT examinations at longer time intervals were also analysed, when available. mECV 
was calculated on scans obtained at 1, and 7 min after contrast injection. 
Results: Thirty-two female patients (aged 57±13 years) with pre-treatment haematocrit 38%±4%, and ejection 
fraction 64%±6% were analysed. Pre-treatment mECV was 27.0%±2.9% at 1 min, and 26.4%±3.8% at 7 min, 
similar to values reported for normal subjects in the literature. Post-treatment mECV (median interval: 89 days after 
treatment) was 31.1%±4.9%, and 30.0%±5.1%, respectively, values significantly higher than pre-treatment values at 
all times (P<0.005). mECV at follow-up (median interval: 135 days after post-treatment CT) was 31.0%±4.5%, and 
27.7%±3.7%, respectively, without significant differences (P>0.548) when compared to post-treatment values.
Conclusions: mECV values from contrast-enhanced CT scans could play a role in the assessment of 
myocardial condition in breast cancer patients undergoing anthracycline-based chemotherapy. CT-derived 
ECV could be an imaging biomarker for the monitoring of therapy-related cardiotoxicity, allowing for 
potential secondary prevention of cardiac damage, using data derived from an examination that could be 
already part of patients’ clinical workflow.
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Introduction
Breast cancer (BC) is the most common cancer in women, 
with 523,000 new cases and 138,000 deaths in Europe 
in 2018 (1). The average woman has a 1 in 8 chance of 
developing BC in their lifetime (2).
Among BC patients,  anthracyclines represent a 
treatment mainstay, used to manage both early state and 
metastatic disease (3,4). However, anthracyclines may 
cause cardiotoxicity expressed as an increase in myocardial 
fibrosis, with a cumulative effect (thought to be irreversible), 
and no options for a safe dosage (5). Fibrosis may lead to 
asymptomatic left ventricular ejection fraction (LVEF) drop, 
hypertension, arrhythmias, QTc-interval prolongation, overt 
heart failure or myocardial ischemia (6,7).
Even though different potential biomarkers for 
chemotherapy cardiotoxicity have been proposed, none has 
so far been proved to be able to timely detect subclinical 
myocardial changes (8). Therefore, there is a need for 
reliable and sensitive biomarkers, which could allow an early 
detection of myocardial changes, to guide physicians in 
undertaking prevention of cardiac dysfunction in women at 
risk (9). Detecting cardiotoxicity in a timely manner would 
in fact allow physicians to undertake preventive measures 
such as the administration of Dexrazoxane (10).
Extracellular volume (ECV) is an imaging biomarker 
which reflects the percentage of myocardium not 
constituted by cells and can increase in presence of fibrosis 
or pathological depositions such as those of amyloidosis 
(11,12). When assessed by cardiac magnetic resonance (CMR) 
through dedicated pulse sequences, ECV has been shown 
to correlate well with histological collagen volume fraction, 
its increase representing a risk factor for heart failure or 
cardiac-related death (13,14). Normal value ranges have been 
proposed as a reference for CMR-derived ECV (15,16). 
Over the last few years, ECV calculation by computed 
tomography (CT) has been also proposed (17). So far, CT-
derived ECV has been assessed through dedicated cardiac 
CT examinations (17). Bandula et al. (18) have shown that 
CT-derived ECV has a robust correlation with both CMR-
derived ECV and histological findings.
In the guidelines for clinical management of BC, 
contrast-enhanced chest CT is recommended for staging or 
restaging at all clinical stages if pulmonary involvement is 
suspected, and it is always recommended for clinical stage 
III patients, albeit not being recommended for screening of 
disease recurrence in asymptomatic patients (3). Notably, 
a standard contrast-enhanced chest CT allows for the 
visualization of the heart, and oncologic CT protocols may 
include a non-contrast scan, an arterial phase scan, a portal-
venous phase scan at 1 min after contrast administration 
and delayed-phase scans from 3 min after contrast 
administration (19), either on both chest and abdomen or 
on the abdomen only. The left ventricle is usually at least 
partially visible even in abdominal scans. 
A key consideration in this context is given by the major 
relevance of cardiac disease in BC survivors. Older women 
diagnosed with BC are almost equally likely to die because of 
BC as they are to die because of cardiovascular disease (20). 
Thus, the aims of our study were: (I) to assess whether 
BC treatment with anthracyclines was associated to 
an increased ECV even in the absence of clinical, 
echocardiographic, or electrocardiographic signs of cardiac 
damage; and (II) to appraise whether any increase in 
myocardial ECV remained unchanged at follow-up. 
Methods
Ethical statement and study design
The local Ethics Committee approved this study (Ethics 
Committee of San Raffaele Clinical Research Hospital; 
protocol code “CardioRetro”, number 122/int/2017; 
approved on September 14th, 2017 and amended on May 
10th, 2018). Due to the retrospective nature of this study, 
specific informed consent was waived. 
Study population
All patients who had undergone anthracycline treatment 
for BC at our institution from May 2012 to May 2018, 
whose contrast-enhanced CT examinations prior to and 
no longer than 5 months after the end of anthracycline 
treatment were available in our database, were included. 
All patients had been treated according to guidelines (3), 
and anthracycline treatment had been administered in 
intravenous bolus for 5 min, once every three weeks. 
Treatment would have been postponed for one week if 
neutrophils were under 1,500/mm3, and the dose would 
have been reduced to 75% in case of febrile neutropenia. 
As per clinical recommendations, CT examinations were 
performed for staging and re-staging patients advanced 
stage disease, or in patients with symptoms of potential 
pulmonary involvement.
Exclusion criteria were the lack of haematocrit value 
obtained from 4 weeks before to the date of the pre-
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treatment CT examination, and further than 4 weeks for 
subsequent examinations or intercurrent surgeries or blood 
transfusions in the time between haematocrit measurements 
and CT scans, as well as incomplete heart scans or the 
presence of artefacts in the longitudinal view of the heart 
in the unenhanced scan or in any of the contrast-enhanced 
scans. Moreover, patients who had undergone radiation 
therapy for cancer in the left breast were excluded due to 
its potential confounding cardiotoxicity (21). Patients also 
underwent an electrocardiogram and echocardiography, and 
patients with underlying cardiac pathology were excluded.
For follow-up assessment, we considered all patients 
having another contrast-enhanced CT examination 
acquired at least 5 months after the end of anthracycline 
chemotherapy and at least 3 months after the first follow-
up CT, so that any leftover myocardial oedema should have 
resolved (22), again excluding those who had undergone 
radiation therapy in the left breast or other cardiotoxic 
chemotherapy or targeted therapy (i.e., trastuzumab), and 
those who either lacked haematocrit values no further 
than 4 weeks from CT examination, or underwent surgery 
or blood transfusion in the time between haematocrit 
measurements and CT scans.
CT acquisition protocol
Patients were studied using 1 of 2 CT scanners, one 
64-slice unit and one 16-slice unit. For the 64-slice CT unit 
(Somatom Definition, Siemens), the following technical 
parameters were used: 120 kVp; tube current from 100 to 
200 mAs, depending on automatic exposure control system 
(CARE Dose 4D, Siemens); rotation time 0.5 s; pitch 1; 
kernel reconstruction technique B30f medium smooth. For 
the 16-slice CT unit (Emotion 16, Siemens), the following 
technical parameters were used: 130 kVp; tube current 
from 100 to 200 mAs, depending on automatic exposure 
control system (CARE Dose 4D, Siemens), rotation time 
0.5 s; pitch 1, kernel reconstruction technique B30f medium 
smooth. All patients underwent total body CT scans 
including abdomen, at least part of the chest and the heart, 
and head. Slice thickness was 5 mm.
An iodinated contrast agent (iopamidol, Iopamiro 370; 
370 mg I/mL; Bracco Imaging) was injected intravenously 
at a dose of 1.2 mL/kg through a 20-gauge needle using 
an automatic injector (EmpowerCTA Contrast Injection 
System, Bracco Imaging) at the rate of 3 mL/s, followed by 
50 mL of saline solution at the same rate.
Scan delay was determined using an automated triggering 
hardware and a dedicated software (Bolus Tracking, Siemens 
Healthineers, Erlangen, Germany). Specifically, low-dose 
monitor images were obtained in a single axial slice of the 
aorta after contrast injection. After obtaining a pre-contrast 
scan, when the descending aorta enhanced more than 
100 Hounsfield unit (HU), the first contrast-enhanced series 
was acquired (arterial phase, about 15–18 s after contrast 
injection). Afterwards, additional scans were acquired for 
obtaining portal venous (1 min after contrast injection) and 
delayed phase at 7 min after contrast injection.
Patients were instructed to hold their breath during 
acquisition and craniocaudal (top-down) scanning direction 
was adopted for all scans. Radiation doses were reported 
using dose-length product (DLP), expressed in mGy × cm, 
and the total DLP value per patient were extracted.
Image analysis
All images were reviewed by a reader with a 2-year experience 
in body CT, and half of them, randomly chosen, were 
reviewed by another reader with a 3-year experience. First, 
the observer chose the best slice to visualize a longitudinal 
view of the cardiac chambers. Then, measurements were 
obtained by manually placing a round region of interest 
(ROI) as large as possible in the mid-level ventricular septum 
and a second ROI in the intraventricular blood pool at the 
same level, again as large as possible but avoiding papillary 
muscles (based on contrast-enhanced scans). This was done 
on scans acquired at 1, and 7 min, as shown in Figure 1. 
Concerning unenhanced scans, ROI placements were copied 
from the 1 min scan, and placed in the same positions, then 
performing subtle adjustments considering density, as the 
myocardium is slightly denser than the blood on basal scans, 
as shown in Figure 2. As scans were not synchronized to an 
electrocardiogram, while placing ROIs, cardiac movement 
was considered: ROIs were mainly placed in the middle of the 
septum, excluding the boundaries close to the intraventricular 
blood pool. 
Septal ECV was calculated using the following formula, 
according to Miller et al. (14):
( ) ( ) ( )1 /post pre post premyo myo blood bloodECV haematocrit HU HU HU HU = − ⋅ − −  [1]
where: myo = myocardium; pre = pre-contrast; post = post-
contrast.
Moreover, we also recorded standard deviations (SD) for 
each ROI placed in the myocardium, and SD of background 
air as a measure of background noise, to appraise a potential 
contamination of measurements of myocardial HUs by 
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Figure 1 Examples of regions of interest used for extracellular volume estimation, in computed tomography scans in a 77-year-old woman: (A) 
at 1 min and (B) at 7 min.
Figure 2 Depiction of region of interest placement on basal and 1 min post-contrast scan in a 30-year-old female patient. The regions of 
interest were first placed in the 1 min scan, where the myocardium and blood were more clearly discernible, and then copied in the same 
positions in the basal scan.
Figure 3 Region of interest placement in a 62-year-old female 
patient, presenting motion artifacts involving the heart. The region 
of interest was placed in the mid-septum, excluding the areas closer 
to the ventricular cavity, where blood contamination was expected.
motion artifacts and subsequent presence of blood in the 
ROI. An example of ROI placement in presence of motion 
artifacts is shown in Figure 3.
Statistical analysis
Continuous variables were tested for normality with the 
Shapiro-Wilk test. Parametric data were reported as mean 
± SD, while non-parametric data were reported as median 
and interquartile range (IQR).
Inter-reader reproducibility of CT-derived ECV was 
assessed in a subset of randomly chosen patients on the pre-
treatment scans, with a two-way, mixed-effects interclass 
correlation coefficient (ICC). ICCs were reported and 
interpreted according to Koo and Li (23). 
Correlations were studied with Pearson r or Spearman ρ 
with regards to data normality. Correlation coefficients were 
interpreted according to Evans (24). When correlations between 
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ECV at different timings were present, Bland-Altman analyses 
were conducted to evaluate data consistency. Differences were 
appraised with t-test when variables were normal, or with 
Wilcoxon’s test when variables were not normal.
Potential contamination of the HUs of the myocardial 
ROIs was studied comparing the ratio between myocardial 
HU SD and background noise, represented by the SD of 
background air, to 1, with a one-sample parametric or non-
parametric test, t-test or Mann-Whitney U respectively, 
with regards to data distribution.
Statistical analysis was performed with SPSS v20 (IBM 
SPSS Inc.). P values <0.05 were considered as significant.
Results
Study population
Based on the availability of studies, 42 female patients were 
originally considered for analysis. After the application 
of exclusion criteria, our population for ECV assessment 
before/after treatment was composed by 32 patients. From 
the initial population, 8 patients were excluded due to 
haematocrit values being out of the desired time interval, 
1 due to incomplete CT scans, and 1 since she underwent 
left radiation therapy. For ECV follow-up, 13 patients were 
excluded for the lack of an additional CT examination at 
appropriate timing and 8 since they underwent left radiation 
therapy between the two CT examinations, leading to 
32 patients being available for ECV comparison between 
pre- and post-chemotherapy, and 11 patients available for 
follow-up analysis (Figure 4).
Age at the first CT was 57±13 years; 29 patients had 
an infiltrating ductal carcinoma, 2 a poorly differentiated 
carcinoma, and 1 a neuroendocrine breast carcinoma. 
All  patients had stage II or higher disease.  Mean 
haematocrit before chemotherapy was 38%±4%, while 
electrocardiogram and echocardiography showed no 
abnormal findings, with a mean LVEF at echocardiography 
of 64%±6%. Baseline characteristics of the study 
population are presented in Table 1. No subject showed 
cardiotoxicity during or after anthracycline treatment, 
defined as a decrease in LVEF of more than 10% to below 
the lower limit of normal (25), and no subject experienced 
symptoms of cardiac toxicity either. All patients underwent 
chemotherapy with dosages adjusted to body weight and 
body surface area according to clinical guidelines (3). No 
patient received reduced doses or less treatment cycles 
due to toxicity. Twenty-six patients received Epirubicin 
at 90 mg/m2 per cycle (total 4 cycles) for a total dose of 
360 mg/m2; 4 patients received mitoxantrone at 10 mg/m2 
per cycle (total 4 cycles) for a total dose of 40 mg/m2; and 
2 received dosages of 60 mg/m2 of Adriamycin per cycle 
(total 4 cycles) for a total dose of 240 mg/m2. Out of 75 total 
CT examinations (32 pre-treatment, 32 post-treatment and 
11 at follow-up), all 75 examinations included the abdomen, 
part of the chest and the heart, and the head. DLP were 
highly variable due to the different CT acquisition protocols 
(chest or abdomen) and total scan volume: mean and SD 
were 3,847±934 mGy × cm, with a minimum DLP value of 
2,093 mGy × cm and a maximum value of 5,680 mGy × cm.
Pre-treatment myocardial ECV and reproducibility
Thirty-two patients were assessed for pre-treatment 
analyses. Pre-treatment ECV was 27.0%±2.9% (mean ± 
SD) at 1 min, and 26.4%±3.8% at 7 min (Figure 5). Inter-
reader reproducibility was good at all scanning times: ICC 
was 0.78 [95% confidence interval (CI): 0.39–0.92] at 1 min, 
and 0.80 (95% CI: 0.42–0.93) at 7 min.
Pre-treatment ECV at 1 min showed significant correlations 
with pre-treatment ECV 7 min (r=0.743, P<0.001). Bland-
Altman analysis between ECV at 1 and 7 min showed a bias of 
0.91% and a coefficient of repeatability of 12%. 
Myocardial ECV after therapy 
The median interval between the end of chemotherapy and 
the first CT after treatment was 89 days (IQR, 23−127 days); 
32 patients were analysed for post-treatment analysis.
Post-treatment haematocrit was 35%±3% (mean ± SD), 
with a significant decrease from pre-treatment values 
(P=0.001). Post-treatment ECV was 31.1%±4.9% at 
1 min, and 30.0%±5.1% at 7 min, values significantly 
higher than those obtained before therapy at all scan times, 
with P<0.001 at 1 min, and P=0.002 at 7 min. The average 
increase in ECV was 4.1% (IQR, 1.2−6.5%), and 2.7% 
(IQR, 0.2−5.9%), respectively (see Figure 5).
Follow-up 
The median interval from post-treatment CT to follow-up 
CT was 135 days (IQR, 116−159 days), the median interval 
from pre-treatment CT to follow-up CT was 312 days 
(IQR, 242−401 days); 11 patients were analysed for follow-
up analyses.
At follow-up, haematocrit was 35%±3% (mean ± SD). 
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Table 1 Baseline characteristics of the study population 
Variable Value (N=32)
Age (years), mean ± SD 57±13
Type of carcinoma
Infiltrating ductal 29
Poorly differentiated 2
Neuroendocrine 1
Disease stage
II 10
III 13
IV 9
LVEF (%), mean ± SD 64±6
Hematocrit (%), mean ± SD 38±4
SD, standard deviation; LVEF, left ventricular ejection fraction.
Figure 4 Flowchart describing patient selection. From the initial population of 42 women complying to inclusion criteria, 10 patients 
were excluded due to: lack of close haematocrit values (n=8); pre-treatment scan not including any analysable portion of the heart (n=1); 
intercurrent radiation therapy to the left breast (n=1). After the post-treatment evaluation, 21 additional patients were excluded due to: lack 
of a further computed tomography examination or close haematocrit (n=13); intercurrent radiation therapy to the left breast (n=8).
Patients fitting according to inclusion criteria
n=42
Patients with hematocrit after the beginning of 
anthracycline treatment or too far from CT
n=8
Patients with incomplete heart scans
n=1
Patients who underwent left radiation therapy
n=1
Patients who did not have an additional CT at 
appropriate timing or close hematocrit values
n=13
Patients who underwent further chemotherapy 
or left radiation therapy
n=8
Patients with hematocrit close to CT
n=34
Patients with visible heart
n=33
Patients with additional CT and hematocrit
n=19
Patients who did not undergo
left radiation therapy
n=32
Patients who did not undergo further
chemotherapy or left radiation therapy
n=11
Figure 5 Boxplot depicting values of myocardial extracellular 
volume (ECV) at 1 min at different time points, namely before 
treatment, after treatment and at follow-up. Individual subjects 
ECV variations are represented by connecting lines.
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The ECV was 31.0%±4.5% at 1 min, and 27.7%±3.7% at 
7 min. There were no significant differences between 
follow-up and post-treatment ECV at 1 min (P=0.669), and 
7 min (P=0.549). Follow-up ECV was significantly higher 
than pre-treatment ECV at 1 min (P=0.002), but not at 
7 min (P=0.288) (see Figure 5). 
Image quality of the myocardium
The median SD of myocardial ROIs was 7.25 HU 
(IQR, 6.26−8.60 HU) for the basal scan, 8.62 HU 
(IQR, 6.74−9.91 HU) at 1 min, and 8.73 HU (IQR, 
7.06−10.11 HU) at 7 min. The median SD of the 
background was 8.45 HU (IQR, 5.98−11.75 HU) for the 
basal scan, 8.98 HU (IQR, 6.33−11.63 HU) at 1 min, and 
9.21 HU (IQR, 6.79−11.76 HU) at 7 min. The median ratios 
between SD of the myocardium and background were 0.92 
(IQR, 0.66−1.18) for the basal scan, 0.96 (IQR, 0.75−1.23) at 
1 min, and 0.96 (IQR, 0.75−1.24) at 7 min, and neither ratio 
was significantly different from 1 (P=0.187, P=0.921, and 
P=0.817, respectively).
Discussion
In this study we demonstrated the feasibility of using ECV 
from CT scans as a biomarker of myocardial condition 
in oncologic patients undergoing potentially cardiotoxic 
chemotherapy.
Our relatively small population can be considered 
representative of the average advanced BC patients in 
terms of age (57±13 years). In fact, women are diagnosed 
with BC at a median age of 61 years, and patients with 
metastatic disease undergoing chemotherapy tend to be 
younger (26,27).  Considering that none of our patients 
was ever reported to have cardiac disease, with normal 
electrocardiogram and LVEF at echocardiography, we can 
assume for their hearts to be healthy prior to chemotherapy.
Our pre-treatment myocardial ECV values are in 
agreement with those reported by Kurita et al. in 14 healthy 
women at 7 min post-contrast injection (28), demonstrating 
that ECV values obtained by body CT are consistent with 
those obtained by dedicated cardiac CT. Our higher limit 
for ECV range compared to the study by Kurita et al. may 
be due to their stricter criteria for cardiac health condition, 
for instance excluding all subjects with a calcium scoring 
≥100. The good inter-reader reproducibility at all scanning 
times suggests that CT-derived ECV should be not only 
accurate but also precise. The positive correlations between 
ECV measured at different times may indicate that all 
values are related to the extent of ECV.
Patients were treated with anthracyclines according to 
current guidelines (3). Although they were treated with 
different drugs, all anthracycline-based drugs have been 
proven to be cardiotoxic at such doses (29). The significant 
difference in ECV between pre- and post- treatment can 
be explained by the known mechanisms of anthracycline 
cardiotoxicity, classified as type I damage according to 
Ewer et al. (30), leading to cell apoptosis and necrosis, thus 
to oedema at acute phase, and consequent fibrosis, both 
determining an increase in ECV (12).
The average increase in ECV we found in this study 
presented a wide distribution of values. This suggests that 
patients may respond differently to anthracycline treatment 
in terms of myocardial oedema and fibrosis, with some 
experiencing a steep increase most likely due to oedema 
and fibrosis following necrosis, and others maintaining a 
constant ECV. In fact, different predictors of anthracycline 
cardiotoxicity have been reported (31), and patients could 
react differently due to pre-existing conditions such as 
diabetes, overweight, smoking, or sedentary life (32). 
An earlier identification of patients more susceptible to 
anthracycline cardiotoxicity may help adopting preventive 
actions, e.g. the administration of cardioprotectors such as 
Dexrazoxane (10). 
Our follow-up results confirmed that CT-derived 
ECV reflects anthracycline cardiotoxicity. Of note, type 
I cardiotoxicity is considered as irreversible (30). Thus, 
since our ECV values did not revert to pre-treatment levels 
months after the end of therapy, we may hypothesize for 
this ECV increase to be permanent or at least markedly 
prolonged. This phenomenon resulted to be clear for ECV 
values obtained at 1 min after contrast injection. For ECV 
values obtained at 7 min, we observed a highly significant 
increase from pre-treatment (26.4%±3.8%) to post-
treatment (30.0%±5.1%) and a reduction to 27.7%±3.7% at 
follow-up, the last value being not significant different from 
that of both pre-treatment and post-treatment. This plays 
in favour of a partial revert of ECV to pre-treatment values 
but also opens the issue of which timing after contrast 
injection is optimal for estimating ECV using CT scans 
before/after the injection of iodinated contrast material, to 
be investigated in future researches. Our timing of 7 min 
is close to the acquisition timing of 5 min post-contrast 
injection which was found to be ideal for calculating ECV 
on CT scans by Treibel et al. (33). Moreover, one study by 
Hamdy et al. (34) showed that delay times of 3, 5, and 7 min 
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after contrast injection provided compatible ECV values, 
and our strong correlation and good agreement between 
values obtained at 1 and 7 min suggests the presence of 
a common denominator which may be evaluated at both 
times. The presence of various scans acquired at different 
times stems from the use of a past imaging protocol, 
including more scans than currently recommended. We 
thus utilized the available scans at different timings to 
evaluate the feasibility of calculating ECV from contrast-
enhanced CT.
The detection of chemotherapy cardiotoxicity has already 
been proposed among the possible clinical uses of ECV (35). 
Indeed, Jordan et al. (36) and Neilan et al. (37), have 
assessed ECV as a biomarker of anthracycline cardiotoxicity 
using CMR T1-mapping before/after the administration of 
gadolinium-based contrast agent. Both studies concluded 
that years after the end of treatment with anthracyclines, 
ECV was still elevated compared to patients not treated 
with cardiotoxic drugs, in agreement with our findings at 
follow-up. However, we should consider that both studies 
assessed myocardial ECV via CMR, which is a relatively 
high-cost examination, not included into the assessment 
of BC patients undergoing chemotherapy. In addition, 
CMR is more time-consuming than CT, it has additional 
contraindications such as obesity or claustrophobia, 
and concerns about the safety of repeated injections of 
gadolinium-based contrast agents have been raised (38).
DLP was elevated and highly variable considering that 
patients underwent different CT protocols on two different 
CT scanners, one of them being an old 16-row unit, and 
all patients performed a total body CT scan (head, chest, 
abdomen and pelvis), reporting in these cases high values of 
DLP, however still under the DRL reverences values (39). 
Nevertheless, an ideal protocol for the analysis of ECV 
on CT would include a basal acquisition on the heart, 
and venous phase scan, totalling around 0.3–0.4 mSv and 
4–5 mSv respectively (40).
Limitations
This study has limitations. First, it is retrospective and 
monocentric, and thus a non-negligible number of subjects 
were not included due to the lack of contemporary 
haematocrit values, scans not sufficiently including the 
heart, or missing CT examinations. These factors reduced 
the sample size, limiting the statistical power, as discussed 
for ECV values obtained at 7 min at follow-up. Moreover, 
haematocrit measurement times were not standardized. 
However, the intrinsic variability of haematocrit is 
estimated to be around 10% as observed by Thirup (41), 
i.e., 0.42 to 0.47, in the absence of significant events as 
bleeding or treatment suppressing the bone marrow. 
Patients who experienced such events were excluded 
from the study as per exclusion criteria, and while their 
timings of haematocrit measurement remain indeed varied, 
we may estimate such variation to be small and follow a 
random pattern, leading to a casual distribution which 
would not affect the eventual mean over the whole sample. 
Nevertheless, this initial experience showed the clinical 
feasibility of myocardial ECV estimate on oncologic CT 
scans. Moreover, while CT is not recommended as a 
screening for disease recurrence, or as a staging and re-
staging imaging technique for asymptomatic, early stage 
BC, a non-negligible number of patients undergoing 
heavily cardiotoxic treatments has advanced disease, 
and CT may indeed be part of their clinical workflow. 
Second, we used two different CT units (64- or 16-slice 
equipment), and our patients had undergone imaging 
according to a past protocol, including scans that are not 
currently recommended for disease staging and re-staging. 
Concerning the CT unit, being densitometry measured 
on CT scans always standardized to the water density (42), 
the measurements should be considered as reliable on both 
units. Regarding the use of an obsolete protocol, the main 
aim of our work was to evaluate feasibility of ECV from 
contrast-enhanced CT, and its results do not imply that a 
proposed prospective protocol for ECV assessment would 
need to include all the acquisitions that were performed 
on our patients. In fact, given the results obtained in the 
study, ECV could likely be calculated only using the 1 min 
scan, representing venous phase and thus recommended 
in staging and re-staging protocols, and one basal slice 
acquired on the heart to obtain pre-contrast HU values. 
Third, image time points were not standardized. However, 
studies on anthracycline cardiotoxicity have shown that it 
is characterized by necrosis and subsequent fibrosis (30), 
thus, knowing that the insult on patients’ hearts ceased 
with the end of chemotherapy, we may assume oedema to 
be resolved by 312 days. Therefore, we may assume that 
our follow-up data reflects irreversible fibrosis. Fourth, 
our images were not triggered ad not synchronized to the 
cardiac cycle. However, we performed measurements to 
mid-septum, thus reducing the impact of this limitation. 
Moreover, we appraised potential contamination of ROI 
values by motion artifacts and presence of blood, by 
analysing the ratio between myocardial SD and background 
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noise and tested the hypothesis that such ratio was equal 
to one, signifying that the two variables were equal and 
thus all the variation in myocardial HUs was due to 
background noise. We found that for every scan timepoint, 
we could not reject the null hypothesis that variation in 
myocardial HUs was compatible with background noise 
(P=0.187, 0.921 and 0.817 for basal, 1- and 7-min scans 
respectively). Another limitation is the lack of a control 
group for ECV comparisons, and of a reference standard 
for our measurements of ECV via contrast-enhanced CT 
scans. However, the former issue is due to the fact that it 
is difficult to include in a retrospective study patients with 
BC who underwent CT and did not undergo treatments 
that may cause cardiotoxicity, as even trastuzumab or 
radiation therapy may bear cardiac-related adverse effects. 
Thus, reference values would need to be established 
via prospective studies before ECV assessment may be 
included in clinical practice. 
In conclusion, we showed that myocardial ECV can 
be estimated on CT scans in BC patients undergoing 
anthracycline-based treatment, and that a significant ECV 
increase can be appreciated after treatment. In a clinical 
perspective, as survival rates for patients diagnosed with 
BC constantly increase, detection of toxicities related to 
treatments become a crucial issue (33). In this setting, 
CT-derived ECV could be an imaging biomarker for the 
monitoring of therapy-related cardiotoxicity, allowing 
for potential secondary prevention of cardiac damage, 
using data derived from an examination that could be 
part of patients’ clinical workflow. Prospective studies are 
warranted to define the role of CT-derived myocardial 
ECV in BC patients.
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